Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.21%
#2 Ocean Protocol Ocean Protocol +21.09%
#3 KUB Coin KUB Coin +18.01%
#4 Audiera Audiera +14.74%
#5 Geodnet Geodnet +13.74%
#6 Arowana Arowana +7.88%
#7 DexNet DexNet +7.78%
#8 Cysic Cysic +7.51%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +7.30%
#10 Ontology Gas Ontology Gas +6.41%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
NuCana plc NuCana plc

NuCana plc

NCNA
Rang in Aktien #32775
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Aktienkurs
$1.51
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$9.14M
Veränderung (1 Tag)
-5.35%
Veränderung (1 Jahr)
-61.11%
Land
GB
Handel NuCana plc (NCNA)

Kategorie

Healthcare
Aktien-Split-Historie für NuCana plc (NCNA)
Die Aktie NuCana plc (Symbol: NCNA) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 18, 2026 statt.
Eine NCNA-Aktie, die vor dem Aug 18, 2026 gekauft wurde, entspricht heute 0 NCNA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR